Emerging Therapies in UC - a podcast by ReachMD

CME credits: 0.25

Valid until: 31-03-2023

Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-uc/13566/

There are over a half dozen newer and emerging classes of agents for ulcerative colitis. This abundance is great news for our patients, but it also increases the complexity of treatment. Listen in as Dr. Neil Nandi and Dr. Jean-Frederic Colombel explore the roles that these agents will play in the evolving treatment landscape.

Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD